Biohaven pharmaceutical holding company q2 adjusted non-gaap loss per share $2.55

Biohaven reports second quarter 2020 financial results and recent business developments.q2 adjusted non-gaap loss per share $2.55.q2 earnings per share estimate $-2.61 -- refinitiv ibes data.q2 loss per share $3.08.q2 revenue $9.7 million.q2 revenue estimate $7.6 million -- refinitiv ibes data.

BHVN Ratings Summary

BHVN Quant Ranking